Table 1 Parameters used in model

Probabilities

Yearly probability of revision surgery on no biologic

0.03894*

[15]

Yearly probability of revision surgery on dupilumab

0.00923

Beta

[10]

Yearly probability of revision surgery on mepolizumab

0.01686

Beta

[10]

Yearly probability of revision surgery on omalizumab

0.02592

Beta

[10]

Yearly probability of rescue OCS on no biologic

0.3196

[10]

Yearly probability of rescue OCS on dupilumab

0.1023

Beta

[10]

Yearly probability of rescue OCS on mepolizumab

0.2173

Beta

[10]

Yearly probability of rescue OCS on omalizumab

0.1950

Beta

[10]

Yearly probability of adverse event on dupilumab

0.3183

Beta

(2, 4.28)

[10]

Yearly probability of adverse event on mepolizumab

0.3183

Beta

(2, 4.28)

[10]

Yearly probability of adverse event on omalizumab

0.3183

Beta

(2, 4.28)

[10]

Proportion of patients non-adherent to dupilumab

0.086

Beta

(2, 21.2)

[11]

Proportion of patients non-adherent to mepolizumab

0.112

Beta

(2, 15.8)

[26]

Proportion of patients non-adherent to omalizumab

0.052

Beta

(2, 36)

[25]

Utilities

SNOT-22 of patients on no biologic

50.11

[10]

SNOT-22 of patients on dupilumab

30.20

Beta

[10]

SNOT-22 of patients on mepolizumab

37.22

Beta

[10]

SNOT-22 of patients on omalizumab

34.02

Beta

[10]

Costs

Cost of ESS in Canada

$3,987

[36]

Cost of biologic complication as anaphylaxis

$1,446

[28]

Cost of biologic complication as arthritis

$3,562

[27]

Cost of biologic complication as conjunctivitis

$179

[30]

Cost of biologic complication as EGPA

$33,292

[29]

Cost of biologic complication as hypersensitivity

$601

[28]

Cost of biologic complication as injection reaction

$601

[28]

Cost of dupilumab (average yearly)

$25,516

Product Monograph (Sanofi-Aventis Canada Inc.)

Cost of mepolizumab (average yearly)

$27,383

Product Monograph (GlaxoSmithKline)

Cost of omalizumab (average yearly)

$20,000

Drug Benefit Prices (Ontario Ministry of Health)